3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells

Cell Proliferation

Volumn 44, Issue 5, 2011, Pages 401-409

  Buommino, E ^a   Tirino, V ^b   de Filippis, A ^a   Silvestri, F ^a   Nicoletti, R ^c   Ciavatta, M L ^d   Pirozzi, G ^b   Tufano, M A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CAT Research Unit ^*  (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLFUNICONE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CD133 ANTIGEN; CD24 ANTIGEN; CD44V ANTIGEN; CELL MARKER; CISPLATIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER STEM CELL; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL EVALUATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLITE; NONHUMAN; PENICILLIUM; PENICILLIUM PINOPHILUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FEMALE; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASTIC STEM CELLS; PENICILLIUM; POLYMERASE CHAIN REACTION; PYRONES; SPHEROIDS, CELLULAR; TELOMERASE; TUMOR STEM CELL ASSAY;

PENICILLIUM PINOPHILUM;

EID: 80053161937     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2011.00766.x     Document Type: Article

References (27)

1. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25.
2. Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673.
3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Visvader DL et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339-9344.
4. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N. Engl. J. Med. 355, 1253-1261.
5. Gupta B, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659.
6. Charafe-Jauffret E, Ginestier C, Birnbaum D (2009) Breast cancer stem cells: tools and models to rely on BMC. Cancer 9, 202.
7. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284.
8. Costea DE, Tsinkalovsky O, Vintermyr OK, Johannessen AC, Mackenzie IC (2006) Cancer stem cells - new and potentially important targets for the therapy of oral squamous cell carcinoma. Oral Dis. 12, 584.
9. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 10, R10.
10. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C et al. (2008) Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int. J. Cancer 122, 298-304.
11. Doyle LS, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358.
12. Szakàcs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234.
13. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 8, 61-70.
14. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
15. Hiyama E, Hiyama K (2002) Clinical utility of telomerase in cancer. Oncogene 21, 643-649.
16. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP et al. (2003) Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 9, 3794-3800.
17. De Stefano S, Nicoletti R, Milone A, Zambardino S (1999) 3-O-Methylfunicone, a fungitoxic metabolite produced by the fungus Penicillium pinophilum. Phytochemistry 52, 1399-1401.
18. Nicoletti R, De Stefano M, De Stefano S, Trincone A, Marziano F (2004) Identification of fungitoxic metabolites produced by some Penicillium isolates antagonistic to Rhizoctonia solani. Mycopathologia 158, 465-474.
19. Stammati A, Nicoletti R, De Stefano S, Zampaglioni F, Zucco F (2002) Cytostatic properties of a novel compound derived from Penicillium pinophilum: an in vitro study. Altern. Lab. Anim. 30, 69-75.
20. Buommino E, Nicoletti R, Gaeta GM, Orlando M, Ciavatta ML, Baroni A et al. (2004) 3-O-methylfunicone, a secondary metabolite produced by Penicillium pinophilum, induces growth arrest and apoptosis in HeLa cells. Cell Prolif. 37, 413-426.
21. Buommino E, Boccellino M, De Filippis A, Petrazzuolo M, Cozza V, Nicoletti R et al. (2007) 3-O-methylfunicone by Penicillium pinophilum affects cell motility of breast cancer cells, down-regulating αVβ5 integrin and inhibiting MMP9 secretion. Mol. Carcinog. 46, 930-940.
22. 2/M arrest and inducing apoptosis. Cell Prolif. 42, 541-553.
23. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Corradini D et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506-5511.
24. Newman DJ, Cragg G, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022-1037.
25. Nicoletti R, Ciavatta L, Buommino E, Tufano MA (2008) Antitumor extrolites produced by Penicillium species. Int. J. Biomed. Pharm. Sci. 2, 1-23.
26. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST et al. (2009) Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4, e8377.
27. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C et al. (2009) Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27, 993-1005.